HIV Treatment Test Closer To Manufacture With New $7.3 Million Grant

February 18, 2009 at 8:00 am Leave a comment

An initiative that is developing a rapid and inexpensive test to analyse the immune system of people living with HIV/AIDS has received a $7.3 million grant from the Bill & Melinda Gates Foundation. If successful, the test would improve healthcare workers’ ability to determine the best treatment for their patients.

The CD4 Initiative at Imperial College London was established to develop an easy to use point-of-care test with a cost of around $2 that can rapidly measure the numbers of CD4+ T-cells in a person’s blood, without using electronics or mechanical parts.

CD4+ T-cells are critical for a healthy functioning immune system and are slowly destroyed during the course of HIV infection. When the numbers of CD4+ T-cells in a person’s blood drop, this makes them increasingly vulnerable to illness. Healthcare workers rely on a CD4 count when making decisions about how HIV-positive patients should be treated and when they should begin antiretroviral therapy. The new test would enable patients to find out within minutes if they should begin antiretroviral treatment.

Imperial’s academic and industrial partners in the CD4 Initiative have worked since 2007 to devise the new test. Teams from Beckman Coulter, Inc (USA), Macfarlane Burnet Institute (Australia) and Zyomyx, Inc (USA) have already developed three prototypes, one of which will be chosen to be manufactured and mass produced in 2010.

The new test will work with a finger-prick blood sample and will have a simple read-out. One of the new prototypes has a design similar to that of a home pregnancy test.

The majority of patients in the developing world do not currently have access to CD4 testing because it is expensive and requires specially trained operators. Where testing facilities exist, it is often too difficult for people in rural areas to reach them. For those who are tested, it can take weeks to obtain results.

“There has been a lot of progress increasing access to life-saving HIV drugs in the developing world, but the lack of access to essential diagnostic tests like a CD4 test is a major barrier to providing the best possible care,” said Dr Hans-Georg Batz, Director of the CD4 Initiative from the Division of Medicine at Imperial College London. “The majority of patients start anti-retroviral therapy based on symptoms alone. Research shows that if you wait until you’re sick to start treatment, you have a much poorer outcome than if you start based on CD4 count. Our new test will have a huge positive impact for people living with HIV across the world.”

Dr Steven Reid, the project manager for the CD4 Initiative at Imperial College London, added: “In resource-poor rural areas, patients sometimes have to walk miles to get to a clinic. Even if a traditional CD4 count is offered, the patients have to come back in a couple of weeks for the result. By then, some are too sick or cannot afford to return. For others, it may already be too late.

“The new test would eliminate the need to wait for treatment. As soon as a patient finds out that they are HIV positive, they could immediately find out if they need to start on antiretroviral therapy,” added Dr Reid.

The CD4 Initiative is a multi-partner, international collaborative effort housed at Imperial College London. A 2005 grant of $8.6m from the Bill & Melinda Gates Foundation supported the first three years of the project. The $7.3 million grant will support trials of the new test in developed and developing world countries, developing the manufacturing process, and initial production runs.

The CD4 Initiative is taking a project management approach to devising the new test. This approach, commonly used in industry, means that multiple research teams from academia, private companies and other institutions around the world work together collaboratively, using strict milestones and set timelines. The CD4 Initiative team believe their success to date demonstrates that this new kind of approach saves both resources and time and could be rolled out to other international health programmes. This public/private sector collaboration is a successful example of this kind of management approach.


Article adapted by Medical News Today from original press release.



1. About the prototype tests

Zyomyx, Inc test – A drop of blood from a fingerprick is mixed with the reagent and then added to the test capillary. After a few minutes, the CD4 T cells accumulate in the capillary and the height of the resulting cell stack corresponds to the number of CD4 T cells in the blood, much like reading a thermometer.

Macfarlane Burnet Institute test – A drop of fingerprick blood is added to the test and after around 30 minutes, a line appears in the test window. If darker than the reference line, the patient does not need to start treatment.

Beckman Coulter, Inc test – A drop of fingerprick blood is added to test and in less than 30 minutes black lines appear in the test window. Two lines indicate a healthy immune system but one line means the patient should start treatment.

2. Consistently rated amongst the world’s best universities, Imperial College London is a science-based institution with a reputation for excellence in teaching and research that attracts 13,000 students and 6,000 staff of the highest international quality. Innovative research at the College explores the interface between science, medicine, engineering and business, delivering practical solutions that improve quality of life and the environment – underpinned by a dynamic enterprise culture.

Since its foundation in 1907, Imperial’s contributions to society have included the discovery of penicillin, the development of holography and the foundations of fibre optics. This commitment to the application of research for the benefit of all continues today, with current focuses including interdisciplinary collaborations to improve health in the UK and globally, tackle climate change and develop clea n and sustainable sources of energy. Website:

Source: Laura Gallagher

Imperial College London



Entry filed under: Uncategorized.

CYPHER SELECT(R) Plus Sirolimus-eluting Coronary Stent Now Approved In The European Union For Treatment Of Patients With Diabetes Arthritis Drug Linked To Shingles Risk

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

Trackback this post  |  Subscribe to the comments via RSS Feed


Top Clicks

  • None

Blog Stats

  • 15,662 hits

%d bloggers like this: